Concepts (171)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| ErbB Receptors | 6 | 2014 | 473 | 1.970 |
Why?
|
| src Homology Domains | 6 | 2017 | 42 | 1.890 |
Why?
|
| Protein Array Analysis | 6 | 2017 | 50 | 1.190 |
Why?
|
| Proteins | 4 | 2017 | 758 | 1.150 |
Why?
|
| Protein Interaction Mapping | 3 | 2017 | 82 | 1.090 |
Why?
|
| Signal Transduction | 8 | 2015 | 3168 | 0.990 |
Why?
|
| Proteome | 4 | 2015 | 108 | 0.920 |
Why?
|
| Blotting, Western | 2 | 2017 | 778 | 0.890 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2017 | 90 | 0.610 |
Why?
|
| Fluorescence Polarization | 2 | 2014 | 9 | 0.610 |
Why?
|
| Quantitative Trait Loci | 3 | 2014 | 555 | 0.570 |
Why?
|
| Proteomics | 3 | 2017 | 193 | 0.560 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2014 | 79 | 0.510 |
Why?
|
| Receptors, Androgen | 1 | 2014 | 91 | 0.500 |
Why?
|
| Phenylethyl Alcohol | 1 | 2012 | 1 | 0.460 |
Why?
|
| Caffeic Acids | 1 | 2012 | 5 | 0.460 |
Why?
|
| Oncogene Protein v-akt | 1 | 2012 | 22 | 0.460 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2012 | 44 | 0.450 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2014 | 200 | 0.450 |
Why?
|
| Receptor, ErbB-2 | 1 | 2012 | 198 | 0.420 |
Why?
|
| Mass Spectrometry | 1 | 2011 | 184 | 0.410 |
Why?
|
| Phosphorylation | 5 | 2014 | 1099 | 0.370 |
Why?
|
| RNA, Messenger | 2 | 2014 | 1942 | 0.370 |
Why?
|
| Cell Proliferation | 3 | 2012 | 1545 | 0.370 |
Why?
|
| Carcinoma | 1 | 2012 | 426 | 0.350 |
Why?
|
| Transcription Factors | 3 | 2014 | 1488 | 0.330 |
Why?
|
| Protein Binding | 5 | 2014 | 1451 | 0.270 |
Why?
|
| Cell Line, Tumor | 6 | 2017 | 2334 | 0.220 |
Why?
|
| Prostatic Neoplasms | 1 | 2012 | 1533 | 0.210 |
Why?
|
| Phosphotyrosine | 2 | 2014 | 34 | 0.200 |
Why?
|
| Systems Biology | 2 | 2011 | 44 | 0.200 |
Why?
|
| gag Gene Products, Human Immunodeficiency Virus | 1 | 2020 | 1 | 0.200 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2020 | 62 | 0.190 |
Why?
|
| Phosphopeptides | 2 | 2012 | 11 | 0.190 |
Why?
|
| Surface Plasmon Resonance | 2 | 2012 | 47 | 0.190 |
Why?
|
| Rhodopseudomonas | 2 | 1989 | 49 | 0.180 |
Why?
|
| Nitrogen Fixation | 2 | 1989 | 37 | 0.180 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2020 | 148 | 0.170 |
Why?
|
| Genetic Variation | 3 | 2014 | 1343 | 0.170 |
Why?
|
| Genes, Bacterial | 2 | 1989 | 195 | 0.170 |
Why?
|
| Cisplatin | 2 | 2017 | 593 | 0.170 |
Why?
|
| Humans | 16 | 2020 | 81624 | 0.160 |
Why?
|
| Genome-Wide Association Study | 3 | 2014 | 1535 | 0.160 |
Why?
|
| Cell Line | 2 | 2014 | 2474 | 0.140 |
Why?
|
| Computational Biology | 2 | 2011 | 519 | 0.140 |
Why?
|
| Genome, Human | 3 | 2014 | 740 | 0.130 |
Why?
|
| Base Sequence | 4 | 2014 | 2331 | 0.130 |
Why?
|
| Breast Neoplasms | 1 | 2008 | 2768 | 0.130 |
Why?
|
| Amino Acid Sequence | 5 | 2010 | 2079 | 0.130 |
Why?
|
| Phosphoproteins | 1 | 2015 | 252 | 0.130 |
Why?
|
| Tyrosine | 1 | 2014 | 138 | 0.130 |
Why?
|
| Toll-Like Receptors | 2 | 2011 | 91 | 0.130 |
Why?
|
| Animals | 9 | 2017 | 25907 | 0.130 |
Why?
|
| Neoplasms, Experimental | 1 | 2015 | 270 | 0.120 |
Why?
|
| Mice, Nude | 2 | 2012 | 764 | 0.120 |
Why?
|
| Chromosome Mapping | 2 | 2014 | 1067 | 0.120 |
Why?
|
| Transcriptome | 2 | 2014 | 527 | 0.120 |
Why?
|
| Molecular Targeted Therapy | 1 | 2015 | 259 | 0.120 |
Why?
|
| RNA Interference | 1 | 2014 | 357 | 0.120 |
Why?
|
| Chromatography, Gel | 1 | 2012 | 103 | 0.120 |
Why?
|
| Cytotoxins | 1 | 2012 | 14 | 0.120 |
Why?
|
| RNA, Small Interfering | 1 | 2014 | 539 | 0.110 |
Why?
|
| Antibodies | 1 | 2014 | 347 | 0.110 |
Why?
|
| Genotype | 2 | 2014 | 1813 | 0.110 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2014 | 289 | 0.110 |
Why?
|
| Pharmacogenetics | 2 | 2014 | 424 | 0.110 |
Why?
|
| HIV Infections | 1 | 2020 | 669 | 0.110 |
Why?
|
| Cell Physiological Phenomena | 1 | 2011 | 23 | 0.110 |
Why?
|
| Neoplasm Proteins | 1 | 2015 | 531 | 0.110 |
Why?
|
| Models, Genetic | 2 | 2014 | 896 | 0.110 |
Why?
|
| Binding Sites | 1 | 2014 | 1084 | 0.100 |
Why?
|
| DNA, Bacterial | 2 | 1989 | 232 | 0.100 |
Why?
|
| Viruses | 1 | 2011 | 75 | 0.100 |
Why?
|
| Sequence Analysis, DNA | 1 | 2014 | 832 | 0.100 |
Why?
|
| Oncogene Proteins v-abl | 1 | 2010 | 2 | 0.100 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2012 | 442 | 0.100 |
Why?
|
| Gene Expression Regulation | 2 | 2017 | 1891 | 0.100 |
Why?
|
| Down-Regulation | 1 | 2012 | 501 | 0.100 |
Why?
|
| Transfer RNA Aminoacylation | 1 | 2009 | 18 | 0.100 |
Why?
|
| Equipment Failure Analysis | 1 | 2010 | 92 | 0.100 |
Why?
|
| Sirolimus | 1 | 2011 | 166 | 0.090 |
Why?
|
| Gene Expression | 1 | 2014 | 1286 | 0.090 |
Why?
|
| Methionine | 1 | 2009 | 66 | 0.090 |
Why?
|
| Mice, Inbred BALB C | 1 | 2012 | 1041 | 0.090 |
Why?
|
| Gene Expression Profiling | 1 | 2015 | 1329 | 0.090 |
Why?
|
| Antineoplastic Agents | 3 | 2017 | 2288 | 0.090 |
Why?
|
| Indoles | 1 | 2011 | 317 | 0.090 |
Why?
|
| Equipment Design | 1 | 2010 | 402 | 0.090 |
Why?
|
| Receptor, ErbB-4 | 1 | 2008 | 5 | 0.090 |
Why?
|
| Dendritic Cells | 1 | 2011 | 421 | 0.090 |
Why?
|
| DNA-Binding Proteins | 1 | 2014 | 1190 | 0.080 |
Why?
|
| Software | 2 | 2015 | 642 | 0.080 |
Why?
|
| Oxidative Stress | 1 | 2009 | 406 | 0.080 |
Why?
|
| Algorithms | 1 | 2015 | 1792 | 0.080 |
Why?
|
| Peptides | 1 | 2010 | 627 | 0.080 |
Why?
|
| Breast | 1 | 2008 | 273 | 0.070 |
Why?
|
| Immunity, Innate | 1 | 2009 | 412 | 0.070 |
Why?
|
| Mice | 4 | 2012 | 10886 | 0.070 |
Why?
|
| Heart | 1 | 2008 | 501 | 0.070 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2014 | 2304 | 0.070 |
Why?
|
| Molecular Sequence Data | 5 | 2010 | 3054 | 0.070 |
Why?
|
| Sensitivity and Specificity | 1 | 2010 | 1946 | 0.070 |
Why?
|
| Peptide Fragments | 2 | 2005 | 458 | 0.070 |
Why?
|
| Magnesium Chloride | 1 | 2004 | 5 | 0.070 |
Why?
|
| Drug Synergism | 2 | 2017 | 305 | 0.060 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2011 | 1047 | 0.060 |
Why?
|
| Fibroblast Growth Factors | 1 | 2004 | 78 | 0.060 |
Why?
|
| Protein Structure, Tertiary | 1 | 2005 | 744 | 0.060 |
Why?
|
| Head and Neck Neoplasms | 1 | 2011 | 1034 | 0.060 |
Why?
|
| Antibodies, Monoclonal | 1 | 2010 | 1378 | 0.060 |
Why?
|
| Reproducibility of Results | 1 | 2010 | 2602 | 0.060 |
Why?
|
| Prognosis | 1 | 2008 | 3562 | 0.050 |
Why?
|
| Genomics | 1 | 2005 | 650 | 0.050 |
Why?
|
| Biomarkers, Tumor | 1 | 2008 | 1413 | 0.050 |
Why?
|
| Viral Load | 1 | 2020 | 138 | 0.050 |
Why?
|
| Anti-HIV Agents | 1 | 2020 | 124 | 0.040 |
Why?
|
| Brain | 1 | 2008 | 2059 | 0.040 |
Why?
|
| Tribolium | 1 | 1997 | 9 | 0.040 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2020 | 406 | 0.040 |
Why?
|
| Hybridization, Genetic | 1 | 1997 | 102 | 0.040 |
Why?
|
| Phenotype | 2 | 2014 | 2294 | 0.040 |
Why?
|
| Lymphocyte Activation | 1 | 2020 | 746 | 0.040 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2020 | 527 | 0.040 |
Why?
|
| Apoptosis | 2 | 2014 | 1655 | 0.040 |
Why?
|
| Male | 3 | 2020 | 39845 | 0.040 |
Why?
|
| Drug Design | 1 | 2015 | 121 | 0.030 |
Why?
|
| HapMap Project | 1 | 2014 | 47 | 0.030 |
Why?
|
| Paclitaxel | 1 | 2014 | 453 | 0.030 |
Why?
|
| Interferon Regulatory Factor-3 | 1 | 2011 | 12 | 0.030 |
Why?
|
| Interferons | 1 | 2011 | 132 | 0.030 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2011 | 121 | 0.030 |
Why?
|
| Sequence Analysis | 1 | 2010 | 26 | 0.030 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2011 | 108 | 0.030 |
Why?
|
| Microarray Analysis | 1 | 2010 | 94 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2011 | 388 | 0.020 |
Why?
|
| MAP Kinase Signaling System | 1 | 2011 | 190 | 0.020 |
Why?
|
| RNA, Transfer, Met | 1 | 2009 | 6 | 0.020 |
Why?
|
| Genetic Code | 1 | 2009 | 25 | 0.020 |
Why?
|
| Orthomyxoviridae | 1 | 2009 | 43 | 0.020 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2011 | 182 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2010 | 351 | 0.020 |
Why?
|
| NADPH Oxidases | 1 | 2009 | 80 | 0.020 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2010 | 418 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2010 | 354 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2011 | 1039 | 0.020 |
Why?
|
| Substrate Specificity | 1 | 2009 | 347 | 0.020 |
Why?
|
| Neovascularization, Pathologic | 1 | 2011 | 337 | 0.020 |
Why?
|
| Female | 4 | 2020 | 42784 | 0.020 |
Why?
|
| Cell Survival | 1 | 2011 | 960 | 0.020 |
Why?
|
| HeLa Cells | 1 | 2009 | 499 | 0.020 |
Why?
|
| Adenoviridae | 1 | 2009 | 345 | 0.020 |
Why?
|
| Ligands | 1 | 2009 | 426 | 0.020 |
Why?
|
| Ribosomal Proteins | 1 | 1987 | 38 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2009 | 449 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2011 | 560 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2010 | 1283 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2011 | 3073 | 0.020 |
Why?
|
| Fibroblast Growth Factor 7 | 1 | 2004 | 9 | 0.020 |
Why?
|
| Culture Media | 1 | 2004 | 144 | 0.020 |
Why?
|
| Heparin | 1 | 2004 | 169 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2004 | 555 | 0.010 |
Why?
|
| Escherichia coli | 1 | 2004 | 597 | 0.010 |
Why?
|
| Middle Aged | 1 | 2020 | 24186 | 0.010 |
Why?
|
| Adult | 1 | 2020 | 24854 | 0.010 |
Why?
|
| Sexual Behavior, Animal | 1 | 1997 | 90 | 0.010 |
Why?
|
| Models, Biological | 1 | 2004 | 1735 | 0.010 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1987 | 174 | 0.010 |
Why?
|
| Species Specificity | 1 | 1987 | 678 | 0.000 |
Why?
|
| Saccharomyces cerevisiae | 1 | 1987 | 430 | 0.000 |
Why?
|
| DNA | 1 | 1987 | 1256 | 0.000 |
Why?
|
| Rats | 1 | 1987 | 3946 | 0.000 |
Why?
|